Key words: arteriovenous malformation; brain abscess; hereditary hemorrhagic telangiectasia; pulmonary; telangiectasia Abbreviations: AVM ϭ arteriovenous malformation; HHT ϭ hereditary hemorrhagic telangiectasia; PFR ϭ pulmonary flow redistribution; TCE ϭ transcatheter embolotherapy; TIA ϭ transient ischemic attack P ulmonary arteriovenous malformations (AVMs) can cause serious neurologic complications (stroke, brain abscess), pulmonary hemorrhage, and hypoxemia. Overall, approximately 30% of patients with pulmonary AVMs will have a history of stroke, 10% of brain abscess, and 10% of pulmonary or pleural hemorrhage. 1 Treatment using transcatheter embolotherapy (TCE) can prevent many of these debilitating and life-threatening complications. In experienced hands, TCE is a safe and efficient procedure for occluding pulmonary AVMs. 1-3 TCE is currently recommended for all pulmonary AVMs with a feeding artery Ն 3 mm. 1 The topic of pulmonary AVMs has recently been extensively reviewed. 4 Some patients with pulmonary AVMs have a more severe and diffuse pattern of disease. Little is known about the clinical characteristics and course of these patients, let alone how they should be managed, because only case reports (a total of 30 patients) appear in the literature, 1,5-25 once cases of hepatopulmonary syndrome are excluded. These patients generally present with exercise intolerance and profound cyanosis and appear to have a poor prognosis. Several (9/30) of the cases were reported to be secondary to hereditary hemorrhagic telangiectasia (HHT). Two cases were related to the polysplenia
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ulmonary arteriovenous malformations (AVMs) can cause serious neurologic complications (stroke, brain abscess), pulmonary hemorrhage, and hypoxemia. Overall, approximately 30% of patients with pulmonary AVMs will have a history of stroke, 10% of brain abscess, and 10% of pulmonary or pleural hemorrhage. 1 Treatment using transcatheter embolotherapy (TCE) can prevent many of these debilitating and life-threatening complications. In experienced hands, TCE is a safe and efficient procedure for occluding pulmonary AVMs. [1] [2] [3] TCE is currently recommended for all pulmonary AVMs with a feeding artery Ն 3 mm. 1 The topic of pulmonary AVMs has recently been extensively reviewed. 4 Some patients with pulmonary AVMs have a more severe and diffuse pattern of disease. Little is known about the clinical characteristics and course of these patients, let alone how they should be managed, because only case reports (a total of 30 patients) appear in the literature, 1, once cases of hepatopulmonary syndrome are excluded. These patients generally present with exercise intolerance and profound cyanosis and appear to have a poor prognosis. Several (9/30) of the cases were reported to be secondary to hereditary hemorrhagic telangiectasia (HHT). Two cases were related to the polysplenia syndrome. Fatal outcomes were reported in 5 of 30 cases, although in general, the follow-up was brief. Little is known about the risk of hemorrhagic and neurologic complications in these patients. Since occlusion or resection of all AVMs in these patients is not realistic, most of the reported patients have gone untreated, and the prognosis is believed to be poor. Some researchers have suggested that lung transplantation should be considered. 12 We reviewed 16 patients with diffuse pulmonary AVMs to assess the natural history in this group, particularly with regard to the risk of neurologic complications. We also wanted to assess whether appropriate management, with the aim of preventing neurologic complications and improving hypoxemia and exercise intolerance, would improve the prognosis.
Materials and Methods
All patients with pulmonary AVMs (n ϭ 351) who were seen in three hospitals (Saint Michael's Hospital, Yale New Haven Hospital, and Johns Hopkins Hospital) between 1980 and 1998 were screened for this study. The patients who were selected included only those with diffuse pulmonary AVMs, defined as AVMs involving every subsegmental artery of at least one lobe (Fig 1) . This is contrasted with the more frequent presentation of multiple discrete pulmonary AVMs (Fig 2) . Five of the patients (patients 3, 4, 6, 9, and 10) have been reported in larger series of pulmonary AVM patients in general, 1, 26 although their clinical and angiographic characteristics were not described.
We reviewed the charts and imaging studies for each patient. The following information was obtained retrospectively from the medical charts: gender; age at presentation; initial Pao 2 ; previous history of complication from pulmonary AVMs, such as stroke, transient ischemic attack (TIA), brain abscess, and hemorrhage; and occurrence of the same complications and Pao 2 measurements during the follow-up period. The patients were also interviewed over the phone for up-to-date follow-up information, and the results of arterial blood gas tests were obtained when possible. The American Thoracic Society dyspnea scale (range of scores, 0 to 4) was used to evaluate current dyspnea levels, 27 although this scale had not been used at the initial presentation. Follow-up time was also calculated from the date of our first assessment, rather than from the initial diagnosis. HHT was diagnosed clinically using current diagnostic criteria. 28 Although some of the patients had received their diagnosis several years previously, we report baseline characteristics as those characteristics that were present when our group first assessed the patient. Imaging was reviewed by the authors (MEF and RIW) to determine the angiographic characteristics of the AVMs (bilateral vs unilateral) and to record all therapy.
All patients were recommended to obtain antibiotic prophylaxis for dental work and other bacteremic procedures. TCE of large pulmonary AVMs (Fig 3) was performed with the goal of preventing paradoxical embolus and stroke or TIA, using the technique previously described. 29 This sometimes required more than one embolization session. Pulmonary flow redistribution (PFR) was developed as an approach to improve hypoxia, as previously described. 30 The patients first underwent a temporary occlusion of lobar arteries (Fig 4) of the most affected lobes (usually both lower lobes) to determine if there was any improve- ment in oxygenation. In those patients whose Pao 2 increased by at least 10 mm Hg, a permanent lobar artery occlusion (Fig 5) was performed.
Results
Of the 351 pulmonary AVM patients who were identified during the 18-year interval, 16 patients (5%; 10 female and 6 male) had diffuse pulmonary AVMs (Table 1) . Of these, HHT was definitively diagnosed in 12 patients (75%) and was suspected in 2 patients (13%). Although many had epistaxis in this group, only one had GI bleeding. Cerebral AVMs were not diagnosed in any of the patients. Interestingly, some had a family history of discrete pulmonary AVMs but none had a family history of diffuse pulmonary AVMs. The mean age at first assessment was 24 years. All patients were cyanotic, and all but one had clubbing. Bilateral diffuse AVMs were present in 14 of 16 patients, whereas 2 of 16 patients had purely unilateral disease. The mean Pao 2 was 47.0 mm Hg. Polycythemia was present in 9 of 12 patients (75%). All patients (11/11) had normal pulmonary artery pressures when measured during angiography. Neurologic complications had occurred in 11 of 16 patients (70%), as detailed in Table 1 . No patient had a history of life-threatening hemorrhage, although 2 of 16 patients (13%) had a history of minor hemoptysis. Of note, six patients had already undergone at least one session of TCE before their initial evaluation with us.
Of the 14 patients with bilateral disease, 12 underwent TCE of the larger pulmonary AVMs. Pao 2 measurements before and immediately after TCE were available in 10 patients (Table 2) and were not significantly different. During the follow-up period, four patients required more sessions of TCE to treat enlarging AVMs. Of the 14 bilateral patients, 5 underwent PFR. Pao 2 measurements before and immediately after PFR were available in four patients and improved by an average of 7.0 mm Hg (p ϭ 0.047; Table 3 ).
In the two patients with uniquely unilateral disease, there was significant improvement in Pao 2 after PFR (patient 15, 58 to 65 mm Hg; patient 16, 53 to 102 mm Hg). In both of these patients, all AVMs that were large enough to undergo TCE were in lobes that were occluded using PFR.
Most of the patients (10/13) reported no persistent improvement in dyspnea with either TCE or PFR, when asked retrospectively. The current average dyspnea score in the 13 living patients is 0.8 ( Table  4) . Eleven of the 13 were working or studying full-time at follow-up. Though some of the patients have desk jobs, one was doing manual labor, one is a paramedic, and one is a nurse. The mean follow-up period was 6 years (range, 0.3 to 17 years), equivalent to 101 patient-years of follow-up (Table 4) . During the follow-up period, there were two episodes of massive hemoptysis and two minor episodes, one brain abscess (in a patient who had not undergone TCE), one stroke, and four TIAs. Massive hemoptysis occurred in patient 2, who had undergone PFR 7 years earlier. On bronchoscopy, patient 2 did not have any telangiectases in the main airways. Her bronchial arteriogram revealed a hypertrophied bronchial artery to the right lower lobe, the site where proximal lobar occlusion (PFR) had been performed. Hemorrhage stopped after embolization of the affected bronchial artery and did not recur over the subsequent 8 months of follow-up. Interestingly, one other patient, who had undergone PFR, developed rib notching on the chest radiograph, although he did not develop hemoptysis. Two other patients in this group (patients 9 and 10) had intermittent minimal hemoptysis; one of these patients was shown to have diffuse telangiectases throughout the tracheobronchial tree on bronchoscopy. The other patient was not investigated.
Three deaths occurred. The 2-year survival rate was 91% (10/11). Patient 4 died of massive hemoptysis 5 years after she was first assessed. She had not undergone any TCE because she had only small diffuse AVMs. She was the first to undergo temporary lobar occlusion; although she had a rise in Pao 2 of 10 mm Hg, at the time this was not judged to be significant enough to warrant PFR. Patient 6 underwent lung transplantation at another center. His intraoperative course was complicated by significant blood loss (which necessitated cardiopulmonary bypass), hypotension, shock, and myocardial ischemia. Despite postoperative extracorporeal membrane oxygenation, he arrested several times and eventually died of multiorgan failure. Patient 14 died at the age of 3 years of congestive heart failure. She had no AVMs large enough for TCE, and her Pao 2 did not improve significantly with temporary lobar occlusions.
Four of the women successfully carried pregnancies to term. Two of these women (patients 7 and 11) delivered without complication before diffuse pulmonary AVMs were diagnosed; therefore, we do not know what their Pao 2 measurements were in retrospect. Patient 16 had four miscarriages before unilateral but diffuse pulmonary AVMs were diagnosed. Her Pao 2 rose to normal levels after PFR. She became pregnant soon after PFR and delivered a normal child at term with no complications. Patient 9 became pregnant, with a Pao 2 ranging from 50 to 60 mm Hg. She became increasingly dyspneic at 32 weeks of pregnancy and had significant peripheral edema. Investigation did not reveal any evidence of congestive heart failure or worsening hypoxia. Her worsening dyspnea was thought to be due to chest wall restriction late in pregnancy. Also, the fetus was noted to have intrauterine growth retardation; therefore, a cesarean section was performed at 33 weeks. The neonate was small for its gestational age but was otherwise well.
Discussion
Pulmonary AVMs are known to cause serious complications. These complications can be prevented if AVMs are managed appropriately with TCE. Little is known about the subgroup of patients with diffuse pulmonary AVMs. Many of the reported patients had a poor prognosis, although few of them had undergone any specific therapy. Their severe hypoxia and our inability to improve it with TCE has led some researchers to suggest that these patients undergo lung transplantation. We have demonstrated that these patients have an increased risk of neurologic complications, but they do have a fairly good prognosis with appropriate management.
We have reviewed our 16 patients with diffuse pulmonary AVMs, describing their clinical characteristics and course with 101 patient-years of follow-up, The majority of our patients with diffuse pulmonary AVMs have HHT, similar to patients with discrete AVMs. The majority had a neurologic complication from pulmonary AVMs by the time of diagnosis, unlike patients with single or multiple discrete pulmonary AVMs. Approximately 40% of patients with pulmonary AVMs will have had a neurologic complication. 1 It is not surprising that the prevalence of neurologic complications is higher in this group, since they may have hundreds of AVMs. Strokes and TIAs are likely caused by paradoxical embolization through the AVM. The pathophysiology of brain abscess is probably different. Abscess formation may result from seeding of bacteria onto areas of encephalomalacia. 31 The encephalomalacia may be caused in turn by previous microemboli, hypoxia, or sludging with polycythemia. Whatever the cause, these patients have a higher prevalence of brain abscess (38%) than reported in the literature (9%) for discrete pulmonary AVMs. 1 As in other series, half of the patients who had a brain abscess had visited the dentist recently. Since both stroke and brain abscess are more frequent in these patients, transcatheter occlusion of the AVMs and antibiotic prophylaxis for bacteremic procedures are justified.
TCE of the large AVMs was performed in all patients. There was no statistically significant improvement in oxygenation after TCE of the large AVMs, which is not surprising since the many tiny diffuse AVMs were unaffected. PFR, a novel approach, was attempted to significantly improve oxygenation. This involved occlusion of lobar arteries to the most severely affected lobes (often the lower lobes), so that pulmonary flow would be redistributed to less-affected areas. Immediately after PFR, there was a small but statistically significant rise in Pao 2 . Of note, these patients had first undergone TCE of the larger AVMs, with no significant change in Pao 2 ; therefore, the rise in Pao 2 was not secondary to the occlusion of the larger AVMs. The fact that the rise in Pao 2 is small reflects the diffuse involvement in this disease. In the two patients who had diffuse disease only unilaterally, the rise in Pao 2 was much greater, indicating that redistribution is technically possible. However, in the remainder of the patients, the disease is too diffuse for redistribution of blood flow to significantly alter the shunt. Although we thought a small improvement in Pao 2 would significantly improve patients' dyspnea, most of the patients did not report any improvement with PFR.
The patients had few serious neurologic events once they were treated. We propose that this is because the larger AVMs had been occluded, thereby reducing the risk of significant cerebral embolization. Despite 101 patient-years of followup, only one new brain abscess occurred, which would suggest that the combination of antibiotic prophylaxis for bacteremic procedures and occlusion Table 1 for abbreviations. †Minor hemoptysis. ‡Mean. §Total events.
As assessed at the end of the follow-up period.
of the larger AVMs is effective in preventing brain abscess. Since brain abscess has a mortality of up to 24%, [32] [33] [34] [35] this is an important event to prevent. Neurologic complications, rather than pulmonary complications, are the rule in this patient population. None of these patients developed spontaneous hemothorax. Two patients had minor hemoptysis; one of the two was shown to have diffuse tracheobronchial telangiectases, which have been previously described in HHT. One patient had massive hemoptysis due to bronchial artery hypertrophy, and one patient developed rib notching after PFR. We do not know whether bronchial artery hypertrophy is part of the disease process or whether it developed subsequent to PFR. Reports in the literature suggest that bronchial artery hypertrophy can occur near untreated pulmonary AVMs 36 or after TCE of pulmonary AVMs. 37 None of the patients who were successfully treated for focal AVMs have ever developed late hemoptysis following TCE. 38 We were surprised by how well these patients function in their daily lives. Few complain of more than mild dyspnea, and the unemployment rate is less than that of the general population. Adaptation to chronic hypoxia is not very well understood. The majority of these patients have polycythemia, which likely helps them to compensate for hypoxia. Those who are not polycythemic have anemia secondary to chronic epistaxis. Pulmonary artery pressures are normal or even reduced in these patients, presumably because of the decreased pulmonary vascular resistance secondary to the diffuse AVMs. Some might expect these patients to develop pulmonary hypertension over time, secondary to the chronic hypoxia; however, these patients do not have alveolar hypoxia. Since hypoxic vasoconstriction occurs secondary to alveolar hypoxia rather than hypoxemia, it is not surprising that these patients do not develop pulmonary hypertension.
Pregnancy in the hypoxic patient is possible, but the rate of fetal loss is increased. This has been best documented in patients with cyanotic heart disease, where only 59% of pregnancies, in women who have not had corrective surgery, have normal fetal outcomes. 39 Two of our patients had a total of five normal pregnancies, years before pulmonary AVMs were diagnosed. In the one cyanotic patient who became pregnant during the follow-up period, intrauterine growth retardation developed, which was likely secondary to fetal hypoxia. As patient 16 exemplifies, hypoxia can also cause infertility. She had multiple miscarriages until her hypoxia was corrected, and then she was able to conceive and have a normal pregnancy.
When confronted with a patient with diffuse pulmonary AVMs, a clinician might incorrectly conclude that such a patient has a poor prognosis and should be referred for lung transplantation. However, the 2-year survival rate in this group (91%) is better than that seen after lung transplantation (63%) 40 ; therefore, referral for lung transplantation does not seem justified. In fact, one of the three deaths in our group occurred after lung transplantation. Survival is likely underestimated in our series because these patients have been referred to tertiary care centers and therefore are likely to be the more severe and symptomatic cases. We have not found any other reports in the literature of lung transplantation for this disease. There may be a time for lung transplantation in these patients, but we have not yet found a marker of disease progression to enable us to determine the most appropriate timing.
Conclusion
Patients with diffuse pulmonary AVMs have a fairly good prognosis and can lead productive lives. In a select group of these patients, small improvements in oxygenation can be obtained with PFR. However, patients with diffuse pulmonary AVMs are at increased risk for neurologic complications; therefore, antibiotic prophylaxis and TCE of the larger AVMs is of utmost importance.
